Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lobbying FDA: AbbVie Questions Humira Biosimilars In Private Meeting

Executive Summary

Switching, manufacturing, and indication extrapolation among worries raised in closed-door session where AbbVie argued Humira's mechanism of action is not entirely understood.

Advertisement

Related Content

Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Biosimilar Interchangeability May Be Losing Luster As Approval Goal
Biosimilar Labeling: Should FDA Just Throw Up Its Hands And Finalize Guidance?
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?
Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?
Biosimilar Manufacturer Reliability Is Key To Market Uptake, Amgen Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS118901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel